Silk Road Medical shares are trading higher after Stifel upgraded the stock from Hold to Buy and raised its price target from $9 to $20.
Portfolio Pulse from Benzinga Newsdesk
Silk Road Medical's stock (SILK) is trading higher following an upgrade from Stifel, moving from a Hold to a Buy rating, with the price target also increased from $9 to $20.
January 19, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silk Road Medical's stock is likely to experience a positive short term impact due to Stifel's upgrade from Hold to Buy and a significant increase in the price target from $9 to $20.
Analyst upgrades and revised price targets are strong indicators that can influence investor sentiment and stock prices. Stifel's upgrade to a Buy rating, coupled with a more than 100% increase in the price target for SILK, is likely to be viewed positively by the market, leading to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100